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Objective: Hemophagocytic lymphohistiocytosis (HLH) is a disorder characterized by uncontrolled
mature histiocyte proliferation, hemophagocytosis, and hypercytokinemia. We describe a previously
healthy pregnant patient who presented in the third trimester of pregnancy with HLH.
Case Report: A 35-year-old woman presented at 38 weeks' gestation with pyrexia, jaundice, severe
anemia, elevated liver enzymes, and lactate dehydrogenase suggestive of HELLP (hemolysis, elevated
liver enzyme, low platelet) syndrome. Unfortunately, her condition deteriorated and she was ventilated
in the intensive care unit despite delivery of the baby and administration of dexamethasone. She
developed microangiopathic hemolytic anemia, thrombocytopenia, and renal impairment suggestive of
thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. However, she was refractory to
plasma exchange, intravenous immunoglobulin, and broad-spectrum antibiotics. HLH was eventually
diagnosed from biochemical and bone marrow ﬁndings. An extensive search for possible causes yielded
negative results. She improved signiﬁcantly with intravenous dexamethasone and cyclosporine A and
was transferred out of the intensive care unit. Unfortunately, she developed cytomegalovirus disease 2
weeks later, which improved transiently with intravenous ganciclovir; later, however, she succumbed to
multidrug-resistant nosocomial infections, rapidly progressive cytomegalovirus disease, and multiorgan
failure.
Conclusion: This case highlights the challenges and difﬁculties involved in the diagnosis and manage-
ment of pregnancy-related HLH. Immunosuppressive treatment for HLH can precipitate life-threatening
opportunistic infections, which need to be promptly diagnosed and treated.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a rare yet
potentially fatal clinicopathological entity because of uncontrolled
immune system activation. It results in histiocytic proliferation
with signiﬁcant hemophagocytic activity in the bone marrow and
massive release of inﬂammatory cytokines [1]. Its diagnosis is based
on the HLH-2004 criteria, which requires at least ﬁve of the
following manifestations: fever  38C, splenomegaly, cytopenia
affecting at least two lineages in the peripheral blood,ment of Medicine, Universiti
Latif, 56000 Kuala Lumpur,
C.L. Wong).
bstetrics & Gynecology. Publishedhypertriglyceridemia and/or hypoﬁbrinogenemia, hemophagocy-
tosis in the bone marrow, spleen, lymph nodes or liver, low or ab-
sent natural killer cell activity, ferritin  500 ng/mL, and elevated
sCD25 [2]. Its incidence worldwide is not known. According to Ishii
et al [3], the annual incidence of HLH in Japan is approximately one
in 800,000.
HLH can be classiﬁed as either primary or secondary. Primary
HLH is an autosomal recessive disorder, also termed familial HLH. It
commonly occurs in infancy and childhood, but can also present
later and is often fatal when untreated [4]. Defects in a number
of genes have been linked to familial HLH: Perforin (PRF1), Munc
13-4 (UNC13D), Syntaxin 11 (STX11), and Munc 19-2 (STXBP2) [2].
Secondary HLH can be triggered by a variety of diseases such
as infections, immunodeﬁciency syndromes, hematological malig-
nancies, and autoimmune diseases. This classiﬁcation is not alwaysby Elsevier Taiwan LLC. All rights reserved.
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underlying genetic mutation is found in only 40% of all primary
HLH patients, and both types could be triggered by a variety of
infections [4]. However, it is useful in long-term management, as
mortality is generally higher in primary HLH unless it is treated by
hematopoietic stem cell transplant.
To date, there are few reported cases of pregnancy-related HLH
that are associated with signiﬁcant morbidity andmortality [5e18].
The majority of cases occurred during the second trimester of
pregnancy (Table 1). The diagnosis of HLH in pregnancy can be
extremely challenging as some of the clinicopathological features
may mimic the presentation of other common conditions exclusive
to pregnancy such as HELLP (hemolysis, elevated liver enzyme, low
platelet) syndrome and acute fatty liver of pregnancy. There are no
established guidelines for the management of pregnancy-related
HLH.
We report our experience in managing a previously healthy
pregnant patient who presented in the third trimester of pregnancy
with HLH. This case highlights the complexity of pregnancy-related
HLH and identiﬁes some key areas in the management of thisTable 1
Summary of reported cases of pregnancy-related HLH.
No. Age (y) Period of
gestation (wk)
Cause/associated factor Treatment
1 28 23 Autoimmune hemolytic
anemia (AIHA)
Steroidsdno response
Termination of pregna
2 32 16 EBV Methylprednisolone 1
3 d þ IV immunoglob
for 3 d þ acyclovir 75
þ gabexate mesilate 2
Maintenance: oral pre
5 mg/d þ camostat m
600 mg/d
3 33 23 B cell lymphoma Steroidsdno response
Six cycles of R-CHOP,
autologous peripheral
cell transplantation
4 a 2nd trimester HSV-2 Acyclovir (750 mg/d)
prednisolone (30 mg/
transient reduction in
IV pulse methylpredn
followed by full-dose
& later cyclosporine A
5 24 29 Necrotizing
lymphadenitisdEBV
IV immunoglobulin 60
IV acyclovir 750 mg e
6 41 19 Twin pregnancy,
history
of Still's disease
High-dose corticostero
7 28 22 SLE IV immunoglobulin 1
then IV methylpredni
for 3 d followed by or
prednisone 0.5 mg/kg
Another 2 doses of IV
28 wk & 30 wk of ges
respectively
8 31 21 HIV & malaria Antimalaria treatmen
(amodiaquine) & HAA
9 a 21 Preeclampsia Antibiotics þ immuno
given but failed
Antithrombin concent
10 30 9 d after delivery Human parvovirus B19 a
11 29 21 Systemic lupus
erythematosus
a
12 36 38 d after delivery Primary Sjogren's
syndrome
Oral prednisolone 1 m
13 33 After delivery SLE Oral prednisolone 55
14 a Second trimester d High-dose IV Ig
EBV ¼ Epstein-Barr virus; HAART ¼ highly active antiretroviral therapy; HLH ¼ hemoph
immunoglobulin; ReCHOP ¼ rituximab, cyclophosphamide, doxorubicin, vincristine, pre
a Information not available.disease that should be addressed in order to improve survival in
this potentially fatal disease.Case Report
A 35-year-old woman presented with a 2-day history of vom-
iting, jaundice, pruritus, and dark-colored urine at 38 weeks'
gestation. Antenatally, she was diagnosed with gestational dia-
betes, which was diet-controlled. During her ﬁrst pregnancy, she
had an emergency cesarean section for severe preeclampsia at 32
weeks' gestation. She denied any abdominal pain, diarrhea, joint
pain, alopecia, malar rash, or bleeding tendency. There was no
history of recent travels, and she was not on any medication. On
examination, she looked pale and jaundiced. She was apyrexial
with a blood pressure of 125/72 mmHg and a heart rate of 100
beats/min. An abdominal examination revealed a gravid uterus
without organomegaly. Examination of other systems yielded un-
remarkable results, and there was no evidence of
lymphadenopathy.Outcome of pregnancy Study
Maternal Fetal
,
ncy
Alive Delivered at 29 wk of
gestationddied from
pulmonary distress
Teng et al [5]
g/d for
ulin 20 g/d
0 mg/d
g/d
dnisolone
esilate
Alive Delivered at 35 wk of
gestationdalive
Mihara et al [6]
then
blood stem
Alive Delivered at 28 wk of
gestation - alive
Hanaoka et al [7]
&
d)/
fever
isolone
prednisolone
Alive Delivered at 37 wk of
gestationdalive
Yamaguchi et al [8]
g/d for 3 d &
very 12 h
Death Delivered at 30 wk
gestationdalive
Chmait et al [9]
ids Alive Delivered at 30 wk of
gestationdalive
Dunn et al [10]
g/kg/d for 2 d
solone 1 g/d
al
/d
Ig given at
tation,
Alive Delivered at 30 wk of
gestationdalive
Perard et al [11]
t
RT
Alive Delivered at termdalive Arewa & Ajadi [12]
globulin
rates
Alive Alive Nakabayashi et al [13]
a a Tsuda et al [14]
a a Hannebicque-
Montaigne et al [15]
g/kg/d Alive Alive Komaru et al [16]
mg/d Alive Alive Yoshida et al [17]
Alive a Gill et al [18]
agocytic lymphohistiocytosis; HSV-2 ¼ herpes simplex virus 2; IVIg ¼ intravenous
dnisolone chemotherapy regimen; SLE ¼ systemic lupus erythematosus.
Figure 1. Photomicrograph of bone marrow aspirate showing macrophages with
hemophagocytic activity (MayeGrunwald stain, 20, original magniﬁcation).
Figure 2. Timeline of the clinical course, laboratory results (platelet, ALP, total
bilirubin, LDH and ferritin) and treatments. Timing of administration and doses of
medications are shown. ALP ¼ alkaline phosphatase; LDH ¼ lactate dehydrogenase.
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cell volume 67.4 fL), white cell count of 15  109/L with predomi-
nantly neutrophils (82.8%), and platelet count of 151  109/L. Pe-
ripheral blood ﬁlm showed hypochromicmicrocytic red blood cells,
anisocytosis, polychromasia, and target and pencil cells. Spher-
ocytes and a few atypical lymphocytes were present, but no frag-
mented red cells were noted. Results of the liver function test was
abnormal: elevated bilirubin of 164 mmol/L (predominantly con-
jugated); alanine transaminase, 341 U/L; aspartate transaminase,
397 U/L; alkaline phosphatase, 389 U/L. The renal proﬁle revealed
an elevated creatinine of 153 U/L and a slightly low sodium level of
131 mmol/L. Lactate dehydrogenase was elevated at 1190 U/L.
Coagulation was abnormal with an elevated prothrombin time of
31.3 seconds (control 12.7 seconds) and an activated partial
thrombin time of 79.3 seconds (control 38.7 seconds). Urine
dipstick showed proteinuria 2þ.
She subsequently underwent an emergency cesarean section
owing to evidence of fetal distress. As there was severe anemia and
coagulopathy, she was transfused with 4 units of packed red blood
cells and 4 units of fresh frozen plasma prior to surgery. Post-
operatively, her Hb and platelet counts dropped further to 4.1 g/dL
and 84 109/L, respectively, within 6 hours. The direct Coombs test
result was negative, and her abdominal ultrasound showed normal
size and echogenicity of the liver and spleen. At this point, the
overall clinical picture was suggestive of HELLP syndrome. Despite
delivery of the baby, she developed disseminated intravascular
coagulopathy, hypovolemic shock, and acute kidney injury with
severe metabolic acidosis requiring ventilator support and
continuous venovenous hemodialysis in the intensive care unit
(ICU). Intravenous dexamethasone 10 mg daily was administered
with minimal improvement.
She received multiple blood product support owing to persis-
tent cytopenias and coagulopathy. On Day 4 postpartum, she sud-
denly developed hemoptysis and acute respiratory distress
approximately 2 hours following transfusion with blood products.
Her chest X-ray results showed diffuse ill-deﬁned opacities at both
lower lung zones, which were most probably attributable to
transfusion-related acute lung injury. She was treated supportively
with oxygen, and her clinical condition stabilized. Although her Hb
level was initially maintained for a few days, she developed a fever
on Day 7 postpartum that was associated with worsening anemia
and thrombocytopenia. Repeat blood ﬁlm showed features
consistent with microangiopathic hemolytic anemia. As blood and
tracheal aspirate culture grew Klebsiella ESBL, the clinical picture
was more suggestive of infection-induced thrombotic thrombocy-
topenic purpura. She was commenced on intravenous broad spec-
trum antibiotics and underwent four cycles of plasma exchange.
She was also treated with intravenous immunoglobulin (IVIg) 10 g
twice a day for 3 days. Despite these measures and massive blood
product support (26 units of packed red blood cells, 45 units of
fresh frozen plasma, 16 units of platelets, and 30 units of cry-
oprecipitate), her condition continued to deteriorate.
Extensive infection screening including blood, urine, and
sputum cultures yielded negative results. Serial full blood count
showed persistent severe anemia (Hb, 5.5 g/dL), severe thrombo-
cytopenia (platelet count, 32  109/L), and leukocytosis. The result
of her liver function test was persistently abnormal with an alanine
transaminase of 158 U/L and aspartate transaminase 74 U/L. Lactate
dehydrogenase was signiﬁcantly elevated at 2692 U/L and C-reac-
tive protein was 1.18 mg/L. The immunoglobulin panel showed
normal IgM, IgG, and IgA levels. A bone marrow biopsy showed
prominent hemophagocytosis with some atypical smear cells
(Figure 1).
On Day 14 postpartum, a diagnosis of HLH was eventually made
that was supported by other blood parameters including lowﬁbrinogen (0.9 g/L), elevated D dimer (19.8 mg/mL), elevated tri-
glyceride (3.45mmol/l), and elevated ferritin (4506 mg/L). Extensive
investigations to search for the underlying cause of HLH were
performed. Autoimmune screening including antinuclear,
antidouble-stranded DNA, anticardiolipin antibody, and rheuma-
toid factor was negative. Serological investigations showed no ev-
idence of active Epstein-Barr virus (EBV), cytomegalovirus disease
(CMV), herpes simplex, dengue, leptospira, hepatitis B, hepatitis C,
VDRL, and Human immunodeﬁciency virus (HIV). Chest X-ray was
normal and abdominal computed tomography showed no hep-
atosplenomegaly or lymphadenopathy. As there was no obvious
evidence of an infectious cause, she was initially treated with
intravenous dexamethasone (16 mg daily) together with intrave-
nous cyclosporine (75 mg twice a day). She improved dramatically,
Figure 3. (A) Colonoscopy ﬁndings showing erythematous rectal wall with ulcers and
bleeding areas. (B) Photomicrograph of colon biopsy showing giant cells with inclusion
body (arrow) characteristic of cytomegalovirus colitis (hematoxylin and eosin
staining, 20, original magniﬁcation).
Figure 4. (A) Chest radiograph showing patchy opacities at both lung ﬁelds, mainly on
the right lung. (B) Computed tomography (CT) of the thorax showing right pleural
effusion and extensive ground glass and interstitial opacities over both lungs.
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complete clinical and biochemical improvement was observed. The
dose of steroids was therefore slowly tapered down, and cyclo-
sporine A was changed to 75 mg twice a day orally (Figure 2).
On Day 31 postpartum, she developed several episodes of fresh
per rectal bleeding from multiple rectal ulcers (Figure 3A) that
required multiple colonoscopies and surgical intervention in an
attempt to control the bleeding. A biopsy of the rectal ulcers
showed CMV inclusion bodies (Figure 3B). Although there was an
absence of anti-CMV IgM antibody, quantitative CMV polymerase
chain reaction from the blood showed a high viral load of > 1
million copies/mL. She also had severe lymphopenia with
lymphocyte counts ranging between 0.2 109/L and 0.4 109/L. As
the HLH was well controlled and in view of the CMV infection,
cyclosporine was stopped and she was treated with intravenous
ganciclovir. On Day 40 postpartum, she developed coarse tremors
of her upper limbs, followed by reduced consciousness level.
Magnetic resonance imaging of the brain showed bilateral occipital
cortical and subcortical hyperintensities, which was suggestive of
posterior reversible leukoencephalopathy. Cerebrospinal ﬂuid
analysis showed normal result. Electroencephalogram did not
show any epileptic discharges. She was reintubated and transferred
back to the ICU. Despite treatment with ganciclovir, she developed
rapidly progressive CMV disease including pneumonitis (Figures 4A
and 4B) and hematuria due to hemorrhagic cystitis. She succumbed
a few days later after developing severe hospital-acquired multi-
drug-resistant Acinetobacter sp. and Klebsiella sp. pneumonia
resulting in septic shock and multiorgan failure.
Discussion
This case illustrates the diagnostic and therapeutic challenges in
the management of HLH in a pregnant lady. According to therevised diagnostic criteria guideline of the HLH-2004 protocol, HLH
is diagnosed if either a genetic ﬁnding consistent with HLH or ﬁve
or more out of eight criteria are fulﬁlled [2]. The clinical and lab-
oratory features of HLH are attributable to organ inﬁltration and
damage and also massive release of proinﬂammatory cytokines
including interferon-g, interleukin-18 and -6, and tumor necrosis
factor a [19]. The organs commonly involved are bone marrow,
liver, spleen, lymph nodes, and central nervous system. This patient
had persistent pyrexia despite treatment with broad-spectrum
antibiotics with negative cultures, bicytopenia (anemia and
thrombocytopenia), hyperferritinemia, hypoﬁbrinogenemia,
hypertriglyceridemia, elevated liver enzymes, and hemophagocytic
activity in her bone marrow. None of these features are speciﬁc for
HLH. However, fever is almost always present in HLH [19]. Nearly all
patients have bicytopenia (usually anemia and thrombocytopenia)
or pancytopenia and elevated serum ferritin (often > 1000 ng/mL
with < 20% as the glycosylated form) [19]. Features suggestive of
HLH are progressive organ involvement, worsening cytopenia,
signiﬁcantly higher than expected ferritin level in inﬂammatory
syndrome or sepsis, worsening liver function, and abnormal
coagulation [20]. Bone marrow and other lymphoid tissues (such as
liver, spleen, and lymph nodes) may show hemophagocytic activity.
Although biopsy-proven hemophagocytosis is regarded as the gold
standard for HLH, it may be absent in the early stage of the disease
[19]. The timing of biopsy from the onset of hemophagocytosis and
the extent of different organ involvement at a particular time
during the course of the disease will inﬂuence the histology results.
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especially when there is a high index of suspicion. Once a diagnosis
of HLH is established, it is crucial to promptly search for an un-
derlying genetic disorder, rheumatological disease, malignancy,
and a triggering infective cause.
Without treatment, the mortality of patients with HLH is high,
particularly in primary HLH and those related to malignancy. Those
with active familial HLH have a survival of ~2 months without
treatment [21,22]. Takahashi et al [1] reported that HLH associated
with lymphomas had a signiﬁcantly higher mortality compared to
HLH because of infections and autoimmune diseases (overall sur-
vival, 8% vs. 83%). Ishii et al [3] reported a 5-year overall survival
rate of 82.7% for EBVeHLH and 89% for other infection-associated
HLH in pediatric and adult patients in Japan. The lowest survival
rate was in T/natural killer cell lymphoma-associated HLH [3].
A comprehensive search of the literature on pregnancy with
HLH was performed using MEDLINE and PubMed databases, and
the ﬁndings were tabulated (Table 1). Ten out of 14 cases occurred
during the second trimester with a range of 16e29 weeks' gesta-
tion. Our patient presented with symptoms in her third trimester.
The pathophysiology of pregnancy-related HLH is not known. It is
not clear whether the pregnancy itself is responsible for or pre-
disposes the mother to HLH. In HLH, CD8þ T cells undergo unreg-
ulated polyclonal expansion and permanent activation after
stimulation by a virus or other factors [19]. This will lead to
excessive macrophage activation and, subsequently, hemophago-
cytosis. In a normal pregnancy, maternal T helper lymphocytes
typically shift from Th1 predominance to Th2 in order to adapt to
the growing fetus in the body [23]. This will result in relatively
decreased cell-mediated immunity (CMI) by Th1 cells with
increased susceptibility to viral infections [23]. Yamaguchi et al [8]
hypothesized that the decreased CMI may allow the overactivation
of hemophagocytes as the ﬁrst immune response to infection
instead of Th1 immune response. These stimulated and uncon-
trolled macrophages also rapidly produce tissue necrosis factor a,
which initiates the inﬂammatory effector pathway. Teng et al [5]
hypothesized that fetomaternal trafﬁcking was the key element
in pregnancy-related HLH and its cytokine storm. Failure of
maternal T lymphocytes to recognize fetomaternal human
lymphocyte antigens and release of trophoblast debris and cyto-
trophoblast cells into maternal circulation may induce an over-
whelming systemic inﬂammatory response, mimicking pregnancy-
related HLH [5]. It is possible that the deterioration of the patient's
clinical condition was aggravated by abnormal fetomaternal cell
trafﬁcking-induced cytokine storm, which was unfortunately re-
fractory to the various treatment modalities given.
Similar to other anecdotal reports, the diagnosis of pregnancy-
related HLH was not suspected in this patient during her initial
presentation because of its rare occurrence and the fact that other
common obstetric emergencies also needed to be considered. In
general, the presence of pyrexia, anemia, thrombocytopenia, and
elevated liver enzymes in a pregnant woman should always raise
the suspicion of HELLP syndrome, acute fatty liver in pregnancy, or
even sepsis. The absence of hypertension and proteinuria has been
documented in HELLP syndrome. Although the clinical features of
pregnancy-related HLH and HELLP syndrome are similar, their
natural course varies. Following delivery of the baby, HELLP syn-
drome usually improves within several days, but HLH may have a
progressive course [9]. Partial HELLP syndromewas the provisional
diagnosis in this patient during the early course of the illness.
However, the subsequent deterioration of her condition despite
delivery of the babymade the diagnosis unlikely. Among the factors
implicated in reported cases of pregnancy-related HLH were vi-
ruses such as EBV, HSV-2, and HIV, B cell lymphoma, and systemic
lupus erythematosus (Table 1).There is no established treatment guideline for pregnancy-
related HLH to date. The aim of treatment in secondary HLH is to
suppress the life-threatening inﬂammatory process driving the
HLH and treat the underlying cause. It is imperative to start treat-
ment as soon as possible. According to the reviewed literature,
treatments included high dose steroids alone [5,10,16,17], steroids
and acyclovir [8], IVIg, steroids and acyclovir [6], IVIg and steroids
[11], IVIg and acyclovir [9], IVIg alone [18], chemotherapy followed
by hematopoietic stem cell transplantation [7], antimalarial and
Highly active antiretroviral therapy (HAART) [12], or antithrombin
[13]. In this patient, high dose dexamethasone and cyclosporine
helped to control her condition. Although steroids are almost al-
ways the choice of treatment in pregnancy-related HLH (Table 1), it
was found to be ineffective in inducing remission in four cases
when given as a monotherapy initially [5e8]. Steroids help to
control the life-threatening hyperinﬂammation as it is cytotoxic to
lymphocytes and inhibits expression of cytokines and differentia-
tion of dendritic cells [24]. In patients with predominant neuro-
logical manifestations, dexamethasone is recommended as it is able
to cross the bloodebrain barrier [18]. Matsuda and Koyasu [25]
reported that the potential effect of cyclosporine A on HLH is
likely inhibition of T cell activation and normalization of the Th2/
Th2 balance. The presence of calcineurin in macrophages/histio-
cytes made these cells susceptible to direct inhibition of cyclo-
sporine A [25]. Treatment with IVIg was found to be ineffective in
this patient. IVIg probably acts via cytokine- and pathogen-speciﬁc
antibodies. IVIg has been shown to improve the outcome of virus-
associated HLH [18,26]. Etoposide is a chemotherapeutic agent that
is highly active in monocytic and histiocytic diseases [24]. However,
it was not administered to our patient because of the risk of
worsening cytopenias, as well as liver and renal impairment.
Immunosuppressive treatment in patients with HLH is a huge
challenge as one has to weigh the balance between controlling the
hyperinﬂammatory process and the risk of opportunistic infection,
worsening cytopenias, and organ impairment as a result of the
treatment itself.
To our knowledge, this is the ﬁrst reported case of pregnancy-
related HLH with subsequent CMV reactivation and infection. The
absence of CMV IgM in the blood and CMV inclusion body in the
bone marrow in the early course of her illness makes it unlikely
as the triggering cause for HLH in this case. The mechanism of
CMV reactivation in this patient was likely to be multifactorial.
She received multiple blood transfusion and had severe lym-
phopenia resulting in reduced CMI. This predisposed her to CMV
infection, which was later conﬁrmed by polymerase chain reac-
tion and the presence of inclusion bodies in the rectal biopsy.
Interestingly, serial CMV serology tests were all negative for both
IgM and IgG. Yamashita et al [27] reported that the mean interval
from the beginning of corticosteroid therapy until the initial
detection of CMV-positive antigenemia was 33 days. In a few
published cases of CMV-associated HLH, the treatment ap-
proaches included IVIg alone [26], ganciclovir monotherapy [28],
and combination of IVIg and ganciclovir [29]. All patients
survived.
Although HLH is invariably known as a life-threatening disease,
there was only one reported mortality in the reviewed cases of
pregnancy-related HLH (Table 1). However, it has been found to
cause signiﬁcant obstetrics complications to bothmother and fetus.
Two had severe preeclampsia, in which one was further compli-
cated with eclampsia, meningeal hemorrhage, and cerebral hem-
orrhage [11]. One patient developed HELLP syndrome and died in
the postpartum course because of coagulopathy and multiorgan
failure [9]. Seven patients had preterm labor, in which four patients
had to undergo emergency cesarean section owing to fetal distress,
reduced fetal movements, and breech presentation [5e7,9e11,13].
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because of its rare occurrence.
In conclusion, HLH should be suspected in a pregnant patient
who has persistent pyrexia, signiﬁcant cytopenias, and organ
enlargement and/or dysfunction with worsening clinical condition
despite delivery of the baby. Secondary causes must be explored
thoroughly, and repeated investigations should be performed as
deemed relevant clinically. Prompt diagnosis and treatment is
extremely essential and should be balanced with the risks of sec-
ondary infections. A different treatment approach may be required
in pregnancy-related HLH; however, this needs to be conﬁrmed in a
larger number of patients.
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